Valuation : Cogent Biosciences, Inc.

Market Cap 6.02B 5.19B 4.88B 4.45B 8.37B 571B 8.41B 57.74B 22.47B 291B 22.6B 22.11B 964B P/E 2026 *
-15.4x
P/E 2027 * -33.1x
Enterprise Value 5.89B 5.08B 4.78B 4.35B 8.19B 559B 8.23B 56.5B 21.99B 284B 22.11B 21.63B 943B EV / Sales 2026 *
983x
EV / Sales 2027 * 20.1x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-0.91%
1 week-5.76%
Current month-0.91%
1 month-10.92%
3 months-0.37%
6 months-10.73%
Current year-2.36%
1 week 34.11
Extreme 34.11
37.66
1 month 34.11
Extreme 34.11
43.39
Current year 30.87
Extreme 30.87
43.39
1 year 11.6
Extreme 11.6
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/27/26 A Exercice

Director

136,530 0.0799%
7/1/26 A Free

Director

627 0.0004%
6/9/26 A Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%-5.76%+187.09%+167.18% 6.02B
-0.25%-4.10%+38.38%+92.61% 68.21B
+2.19%+0.89%+49.44%+90.69% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+2.19%+1.44%+32.57%-17.76% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average +0.17%-4.11%+59.87%+200.42% 26.91B
Weighted average by Cap. +0.46%-3.28%+45.37%+159.32%

Financials

2026 *2027 *
Net sales 5.99M 5.17M 4.86M 4.43M 8.32M 568M 8.37M 57.45M 22.36M 289M 22.48M 22M 959M 293M 253M 238M 216M 407M 27.78B 409M 2.81B 1.09B 14.13B 1.1B 1.08B 46.86B
Net income -399M -344M -324M -295M -555M -37.86B -558M -3.83B -1.49B -19.26B -1.5B -1.47B -63.86B -202M -174M -164M -149M -280M -19.13B -282M -1.93B -752M -9.73B -757M -740M -32.26B
Net Debt -130M -112M -105M -95.84M -180M -12.3B -181M -1.24B -484M -6.26B -487M -476M -20.75B -126M -109M -102M -93.22M -175M -11.97B -176M -1.21B -471M -6.09B -473M -463M -20.19B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
01/09/26 $34.68 -0.91% 1,480,641
31/08/26 $35.00 +0.95% 1,849,678
28/08/26 $34.67 -6.52% 1,771,221
27/08/26 $37.09 +1.01% 1,636,565
26/08/26 $36.72 -0.22% 1,062,781
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
34.68USD
Average target price
55.82USD
Spread / Average Target
+60.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock